Diabetes Nutritional, Metabolic, Endocrine Diabetes
Conditions
Interventions
The TOGETHER project will employ participatory methods to co-design, deliver and evaluate a new model of group clinic-based diabetes care that addresses the needs of young people (aged 16–25 years) fr
staff and patients then work together to identify the priorities for service development. The EBCD process is iterative, allowing ongoing redesign and adaptation throughout the process of implementing
Sponsors
Queen Mary University of London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged 16-25 with diabetes, patient representatives, health care professionals and community-based organisations
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantitative outcomes: The study is not powered to detect a difference in quantitative outcomes and these will be used to guide future at-scale evaluation, e.g. a cluster randomised trial. Quantitative data will be collected from all group clinic and control participants at study entry and annually whilst they are in the study. Data collected will include: 1. Biological markers of diabetes care and control: HbA1c, foot check, retinal screening, blood pressure, cholesterol, frequency of blood glucose self-monitoring, severe hypoglycaemia, medication history, attendance at structured education, other medical conditions, diabetes technology used 2. Administrative activity and cost data: attendance rates at scheduled care, unscheduled care contact, staff contact time 3. Experience: Problem Areas In Diabetes (PAID) scale, Patient Enablement Instrument (PEI), analogue rating of overall clinical care (0-10) Qualitative outcomes: 1. Attitudes to, experience, and perceptions of the new care model (group clinics), and the active ingredients of their success, assessed through interview and direct observation throughout the course of the study, and will include participants from all 3 groups (co-design, group clinics and control) described above | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The feasibility and acceptability of collecting high-quality data on the proposed clinical, process and cost-related outcomes, and what sample size might be required to design a scaled-up cluster randomised trial of the group clinic model 2. Clinical outcomes, process and cost data from participants in the group clinics model and control participants at other designated units running similar clinics for young adults with diabetes Timepoint(s): October 2019 | — |
Countries
England, United Kingdom
Contacts
Public ContactSarah Finer
Outcome results
None listed